<DOC>
	<DOCNO>NCT00000762</DOCNO>
	<brief_summary>To determine safety immunogenicity gp160 ( MicroGeneSys ) , rgp120/HIV-1MN ( Genentech ) , rgp120/HIV-1SF2 ( BIOCINE ) adjuvants HIV-infected child 1 month 18 year age . The initiation immunotherapy trial provide multiple benefit assess asymptomatic HIV-infected child therapy currently test adult counterpart , hope forestall progression HIV immunosuppression clinical disease .</brief_summary>
	<brief_title>A Placebo-Controlled , Phase I Clinical Trial Evaluate Safety Immunogenicity Recombinant Envelope Proteins HIV-1 gp160 gp120 Children &gt; = 1 Month Old With Asymptomatic HIV Infection</brief_title>
	<detailed_description>The initiation immunotherapy trial provide multiple benefit assess asymptomatic HIV-infected child therapy currently test adult counterpart , hope forestall progression HIV immunosuppression clinical disease . Patients randomize receive one three vaccine ( 9 patients/vaccine ) adjuvant placebo ( 3 patients/vaccine ) . The vaccine study low high dos . When three four patient low dose vaccine receive two immunization without evidence dose-limiting toxicity , dose escalation high dose vaccine initiate subsequent patient cohort , provide low dose arm fill . A total six immunization give , 0 , 4 , 8 , 12 , 16 , 24 week . Patients follow 24 week last immunization .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : PCP prophylaxis . Patients must : Documented asymptomatic HIV infection . CD4+ count follow : 111 month age must &gt; 2000 cells/mm3 &gt; = 30 percent total lymphocyte ; 1223 month must &gt; 1000 cells/mm3 &gt; = 20 percent total lymphocytes ; 24 months6 year must &gt; 750 cells/mm3 &gt; = 20 percent total lymphocytes ; 7 year old must &gt; 500 cells/mm3 &gt; = 20 percent total lymphocyte . NOTE : Patients receive zidovudine 3 consecutive month immediately prior study entry may receive high dos vaccine . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Any serious acute infection . Concurrent Medication : Excluded : Anticipated steroid therapy &gt; 6 week duration . Excluded within past 2 year : More one serious proven bacterial infection sepsis , pneumonia , meningitis , bone joint infection , abscess internal organ body cavity ( otitis medium superficial skin mucosal abscess ) cause Haemophilus , Streptococcus , Pneumococcus , pyogenic bacteria . Prior Medication : Excluded : Antiretroviral therapy immunomodulators ( e.g. , IVIG ) within 1 month prior study entry ( NOTE : AZT allow within 1 month prior study entry patient enter highdose arm ) . Uninterrupted steroid therapy &gt; 6 week duration .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV Envelope Protein gp160</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>